Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Front Pharmacol ; 13: 981978, 2022.
Article in English | MEDLINE | ID: mdl-36249773

ABSTRACT

Dietary supplement current good manufacturing practice (cGMP) requires establishment of quality parameters for each component used in the manufacture of a dietary supplement to ensure that specifications for the identity, purity, strength, composition, and limits on contaminants are met. Compliance with botanical extract ingredient specifications is assured by using scientifically valid methods of analysis, the results of which are reported on certificates of analysis (CoAs). However, CoAs routinely include additional data that are not amenable to verification through methods of analysis. Such descriptive information may include Plant to Extract ratios, which are ratios of the quantity of botanical article used in the manufacture of the extract to the quantity of extract obtained. Plant to Extract ratios can be misleading when their meaning is not clearly understood. Plant to Extract ratios do not completely describe botanical extracts because other important factors influence the make-up of final extracts, such as the quality of the raw starting material (as can defined by pharmacopeial standards), extraction solvent(s) used, duration and temperature of extraction, and percentage and type of excipients present. Other important qualitative descriptions may include constituent "fingerprinting." Despite these issues, Plant to Extract ratios are often used as a measure of extract strength for dosage calculations. This article defines and clarifies the meaning of Plant to Extract ratios and their proper use in describing and labeling botanical extract ingredients and finished products containing them.

2.
Curr Neuropharmacol ; 19(9): 1384-1400, 2021.
Article in English | MEDLINE | ID: mdl-33588735

ABSTRACT

Modern-day regulatory systems governing conditions for how health products enter national markets constitute a barrier of access for traditional herbal medicines on an international level. Regulatory intentions are focused on ensuring that consumers are being provided with safe, efficacious and high-quality products that, however, collaterally limit opportunities for traditional herbal medicinal products, especially those that do not already have a long-standing tradition of use established in the respective national marketplaces. This case study investigates and compares how a Southern African herbal medicine with great potential as an anxiolytic and mild antidepressant - Mesembryanthemum tortuosum L. [syn. Sceletium tortuosum (L.) N.E.Br.] aerial parts - fares internationally in today's regulatory environments. It is argued that inadvertent regulatory favoritism combined with the lack of means for adequate protection of intellectual property may obstruct innovation by creating an almost insurmountable economical hurdle for successful product development and introduction of botanicals from developing countries into most of the world's health product markets.


Subject(s)
Cognitive Dysfunction , Mesembryanthemum , Anxiety , Depression/drug therapy , Herbal Medicine , Humans , Plant Extracts
4.
Planta Med ; 86(1): 10-18, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31731314

ABSTRACT

The recent publication of a World Scientists' Warning to Humanity highlighted the fact that climate change, absent strenuous mitigation or adaptation efforts, will have profound negative effects for humanity and other species, affecting numerous aspects of life. In this paper, we call attention to one of these aspects, the effects of climate change on medicinal plants. These plants provide many benefits for human health, particularly in communities where Western medicine is unavailable. As for other species, their populations may be threatened by changing temperature and precipitation regimes, disruption of commensal relationships, and increases in pests and pathogens, combined with anthropogenic habitat fragmentation that impedes migration. Additionally, medicinal species are often harvested unsustainably, and this combination of pressures may push many populations to extinction. A second issue is that some species may respond to increased environmental stresses not only with declines in biomass production but with changes in chemical content, potentially affecting quality or even safety of medicinal products. We therefore recommend actions including conservation and local cultivation of valued plants, sustainability training for harvesters and certification of commercial material, preservation of traditional knowledge, and programs to monitor raw material quality in addition to, of course, efforts to mitigate climate change.


Subject(s)
Climate Change , Plants, Medicinal , Conservation of Natural Resources , Extinction, Biological
5.
Clin Pharmacol Ther ; 104(3): 435-445, 2018 09.
Article in English | MEDLINE | ID: mdl-29947417

ABSTRACT

Several Cinnamomum species' barks are generally labeled as cinnamon, although only Cinnamomum verum carries the common name of true cinnamon. Cassia, a common name for a related species, is rarely used on labels; instead, various cassia types may also be labeled "cinnamon." Confusion of true cinnamon and cassia spices in foods generally does not present a risk to health, except possibly at the highest intake levels. However, clinical studies with Cinnamomum investigational products have been published that inadequately describe or lack botanical identification information. The results of such studies are confounded by an inability to determine which species was responsible for the observed effects. Due to differences in the quality and composition of various Cinnamomum species, safety and efficacy data are not generalizable or transferable. Pharmacopeial monographs for characterizing the identity, composition, purity, quality, and strength of Cinnamomum investigational products should be applied to remove the ambiguity of cinnamon.


Subject(s)
Cinnamomum zeylanicum/classification , Clinical Trials as Topic/methods , Evidence-Based Medicine/methods , Phytotherapy/classification , Plant Preparations/classification , Research Design , Terminology as Topic , Cinnamomum zeylanicum/adverse effects , Clinical Trials as Topic/standards , Commerce , Consensus , Consumer Product Safety , Drug Costs , Evidence-Based Medicine/standards , Humans , Patient Safety , Phytotherapy/adverse effects , Phytotherapy/economics , Phytotherapy/standards , Plant Preparations/adverse effects , Plant Preparations/economics , Plant Preparations/standards , Research Design/standards , Species Specificity
6.
PLoS One ; 12(9): e0184791, 2017.
Article in English | MEDLINE | ID: mdl-28945770

ABSTRACT

Astragalus mongholicus Bunge (Fabaceae) is an important plant source of the herbal drug known as Radix Astragali, which is used worldwide as a medicinal ingredient and a component of food supplement. Russian Federation, Mongolia, Kazakhstan, and China are the main natural distribution areas of A. mongholicus in the world. However, the quality of medicinal plant varies among different locations. As for A. mongholicus, limited literature focused on its biodiversity mechanism. Here, we combined the chemometric analysis of chemical components with genetic variation, as well as climatic and edaphic traits, to reveal the biodiversity mechanism of A. mongholicus. Results showed that the detected chemical, genetic and climatic traits comprehensively contributed to the quality diversity of A. mongholicus. The eight main chemical components, as well as the inorganic elements of P, B and Na were all significant chemical factors. The precipitation and sunshine duration were the main distinguishing climatic factors. The inorganic elements As, Mn, P, Se and Pb were the distinguishing edaphic factors. The systematic method was firstly established for this medicinal plant in order to illustrate the formation of diversity in terms of quality, and provide scientific evidence for geographic indications and climatic adaptation in production and in the clinical application of herbal medicinal plants.


Subject(s)
Astragalus Plant/metabolism , Genetic Variation , Astragalus Plant/chemistry , Astragalus Plant/genetics , China , Climate , DNA, Plant/genetics , Ecology , Genetic Variation/genetics , Glucosides/analysis , Isoflavones/analysis , Kaempferols/analysis , Plants, Medicinal/genetics , Plants, Medicinal/metabolism , Polymerase Chain Reaction , Quercetin/analysis , Sequence Analysis, DNA
7.
J Chromatogr A ; 1426: 1-15, 2015 Dec 24.
Article in English | MEDLINE | ID: mdl-26643719

ABSTRACT

Panax quinquefolius (PQ) is one of the best-selling natural health products due to its proposed beneficial anti-aging, anti-cancer, anti-stress, anti-fatigue, and anxiolytic effects. In recent years, the quality of PQ has received considerable attention. Sensitive and accurate methods for qualitative and quantitative analyses of chemical constituents are necessary for the comprehensive quality control to ensure the safety and efficacy of PQ. This article reviews recent progress in the chemical analysis of PQ and its preparations. Numerous analytical techniques, including spectroscopy, thin-layer chromatography (TLC), gas chromatography (GC), high-performance liquid chromatography (HPLC), liquid chromatography/mass spectrometry (LC/MS), high-speed centrifugal partition chromatography (HSCPC), high-performance counter-current chromatography (HPCCC), nuclear magnetic resonance spectroscopy (NMR), and immunoassay, are described. Among these techniques, HPLC coupled with mass spectrometry (MS) is the most promising method for quality control. The challenges encountered in the chemical analysis of PQ are also briefly discussed, and the remaining questions regarding the quality control of PQ that require further investigation are highlighted.


Subject(s)
Biological Products/analysis , Biological Products/standards , Panax/chemistry , Plant Extracts/analysis , Chromatography, High Pressure Liquid , Chromatography, Thin Layer , Humans , Magnetic Resonance Spectroscopy , Mass Spectrometry , United States
8.
J Altern Complement Med ; 15(1): 67-77, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19769479

ABSTRACT

OBJECTIVE: The southern U.S. region has among the highest incidence of chronic rhinosinusitis (CRS). Historically, African Americans in this region have been a difficult to reach population for clinical research participation. This study's aim was to observe any association between herbal tea consumption and CRS symptoms among African Americans. We recount the volunteers self-reporting of measurements associated with self-treatment of CRS symptoms. DESIGN: The study design was a preliminary, open-label, pilot study. SETTINGS: Volunteers were drawn from Morehouse School of Medicine's outpatient clinics, community multipurpose senior centers, and churches in Fulton and DeKalb Counties, GA. SUBJECTS: One hundred (100) African American volunteers were prescreened, of whom 55 with a clinical diagnosis of CRS met entrance criteria. INTERVENTION: Volunteers self-administered Breathe Easy herbal tea for a duration of 6 weeks. OUTCOME MEASURES: The Chronic Sinusitis Survey (CSS) scale was administered to assess sinus health at baseline and term and overall quality of life was assessed using the Short Form-36 (SF-36) index. RESULTS: Of the 55 volunteers who met entrance criteria, 41 completed the study; groups were q.i.d. (n = 27), t.i.d. (n = 4), b.i.d. (n = 5), and noncompliant (n = 5). For the q.i.d. group (n = 27), there was a significant increase in the CSS symptom score (difference in means 22.0 points; p = 0.020) and CSS total score (11.1 points; p = 0.020). Overall health status (SF-36) reported at baseline was 35% very good; 34% good; and 17% fair. After 6-weeks, the q.i.d. group showed a significant change to 44% good and 45% very good (p = 0.001). CONCLUSIONS: This preliminary pilot study suggests that q.i.d. self-administration of Breathe Easy was associated with improved volunteers' sinus health status (e.g., ability to fall sleep). Our results suggest that this herbal tea may contribute as a complementary therapy for management of CRS among African Americans. To further assess efficacy and applicability to other populations, randomized controlled trials in larger populations are warranted.


Subject(s)
Beverages , Black or African American , Magnoliopsida , Phytotherapy , Plant Extracts/therapeutic use , Quality of Life , Sinusitis/drug therapy , Adult , Aged , Chronic Disease , Complementary Therapies , Female , Georgia/ethnology , Health Status , Health Surveys , Humans , Male , Middle Aged , Pilot Projects , Self Medication , Sinusitis/ethnology
9.
J Am Med Dir Assoc ; 7(9): 556-61, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17095420

ABSTRACT

OBJECTIVE: To investigate the efficacy and cost effectiveness of an herbal tea, Smooth Move, in nursing home residents with chronic constipation. DESIGN: Double-blind, placebo-controlled, 2-armed, parallel-group clinical trial. SETTING: A 483-bed nursing home in Allentown, Pennsylvania, operated by Lehigh County Government. PARTICIPANTS: A total of 86 nursing home residents with chronic constipation. INTERVENTIONS: Participants (n = 86) were randomly assigned to receive Smooth Move (n = 42) or a placebo (n = 44), once daily, in addition to standard treatment for chronic constipation. The study period was 28 days. MEASUREMENTS: The primary efficacy parameter was the difference in total number of bowel movements. Secondary parameters included the difference in average number of standard treatment doses dispensed, and the difference in total medication costs. RESULTS: Compared to placebo, in the intention to treat (ITT analysis) there was a statistically significant increase in the number of bowel movements in the Smooth Move group. The Smooth Move group (n = 42) compared with the placebo group (n = 44) experienced an average of 4.14 more bowel movements during the 28-day study period versus the 28-day pre-study period (P = .017). CONCLUSION: Smooth Move herbal tea, when added to the standard treatment regimen for nursing home residents with chronic constipation, increased the average number of bowel movements compared to the addition of a placebo tea.


Subject(s)
Beverages/standards , Constipation/prevention & control , Dietary Supplements/standards , Nursing Homes , Phytotherapy/methods , Beverages/economics , Chronic Disease , Cinnamomum aromaticum , Citrus sinensis , Constipation/etiology , Coriandrum , Defecation/drug effects , Dietary Supplements/economics , Double-Blind Method , Female , Foeniculum , Fruit , Zingiber officinale , Glycyrrhizic Acid/therapeutic use , Gum Arabic , Humans , Male , Pennsylvania , Phytotherapy/economics , Plant Bark , Risk Factors , Treatment Outcome
11.
J Altern Complement Med ; 9(2): 285-98, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12804082

ABSTRACT

OBJECTIVE: To investigate the safety and efficacy of Throat Coat) (Traditional Medicinals,) Sebastopol, CA), a traditional demulcent herbal tea, in comparison with a placebo tea in the symptomatic treatment of acute pharyngitis. DESIGN: Multicenter, prospective, randomized, double-blinded, placebo-controlled, two-armed, parallel-group clinical trial. SETTINGS: Three primary care clinics in Duluth, MN, Madison, WI, and Middleton, WI. SUBJECTS: Patients of both genders (>or=18 years of age) with clinical diagnoses of acute pharyngitis. INTERVENTIONS: Patients (n = 60) were randomly assigned to receive 5-8 oz of Throat Coat (n = 30) or a placebo (n = 30), four to six times daily. The study period was 2 to 7 days with a window for the follow-up visit of 2-10 days accounting for the variable duration of sore throat symptoms. OUTCOME MEASURES: Primary efficacy parameter: sum of pain intensity differences (SPID) for pain in throat on swallowing, calculated as the area under the curve (AUC) of pain intensity difference scores (assessed at 1 minute, 5 minutes, 10 minutes, 15 minutes, 20 minutes, and 30 minutes after treatment). Secondary efficacy parameter: total pain relief (TOTPAR), calculated as the AUC from time 0 (baseline) to 30 minutes of pain relief (assessed at 1 minute, 5 minutes, 10 minutes, 15 minutes, 20 minutes, and 30 minutes). RESULTS: Compared to placebo, intensity of throat pain when swallowing was significantly reduced by Throat Coat in intention to treat and valid for efficacy analysis (VEA). Significant differences in change from baseline pain were observed at 5 min (p = 0.007), 10 min (p = 0.005), 15 minutes (p = 0.01), 20 minutes (p = 0.05), and 30 minutes (p = 0.04) after completion of the first dose (VEA analysis). There was a statistically significant improvement of SPID in the Throat Coat-treated group: Least square means +/- standard error of the means (SEM) of SPID were -16.5 +/- 13.9 in the placebo group and -43.8 +/- 11.9 in the Throat Coat-treated group (p = 0.012). TOTPAR was also significantly higher in the Throat Coat-treated group: Least square means +/- SEM of TOTPAR were 32.4 +/- 12.8 in the placebo group and 53.6 +/- 10.9 in the Throat Coat-treated group (p = 0.031). This study shows that Throat Coat is significantly superior to placebo and provided a rapid, temporary relief of sore throat pain in patients with pharyngitis.


Subject(s)
Analgesics/administration & dosage , Pharyngitis/drug therapy , Phytotherapy , Plant Extracts/administration & dosage , Plants, Medicinal , Acute Disease , Administration, Oral , Adult , Area Under Curve , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Male , Pain Measurement/drug effects , Patient Satisfaction , Prospective Studies , Surveys and Questionnaires , Time Factors , Treatment Outcome , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...